Organicell Regenerative Medicine (OTCBB: BPSR), a clinical-stage biopharma company developing exosome-based regenerative therapies, has announced the release of a Case Report in the peer reviewed journal Frontiers in Medicine. This case study highlights the therapeutic potential of Organicell’s proprietary therapeutic, Zofin™, and its continued success as a drug candidate. [Read more…]
Kimera Labs Introduces the Ross Unit, a Standard Measurement for Exosome Potency and Characterization
Although long overlooked, exosomes have been gaining momentum due to their potential for use as cell-free therapeutics. Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. [Read more…]
Ciloa’s project among the 11 winners of the “Sanofi iTech Awards”
-
French biotech company Ciloa wins the 2020 “Sanofi iTech Awards”.
-
The winning project is based on the unique innovation developed by Ciloa, which uses its customized exosomes for therapeutic purposes.
-
The “Sanofi iTech Awards” program funds and supports projects related to the development of innovative technologies in Healthcare that may lead to a subsequent research collaboration between Sanofi and Ciloa.
Organicell Announces FDA Approval Of IND Application for the Use of Zofin™ In The Treatment Of Chronic Obstructive Pulmonary Disease (COPD)
Miami, FL (January 28th, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of patients diagnosed with chronic obstructive pulmonary disease (COPD). [Read more…]
JOP POST: Chief Manufacturing & Development Officer at Exopharm
Job Title: Chief Manufacturing & Development Officer
Company: Exopharm
- Exosome therapeutic bioproducts
- World leader and innovator
- Listed company based in Melbourne Australia
- Lead the 20 person innovation and development team in this expanding biotech
Established in 2013 and listed in 2018, Exopharm (ASX:EX1) was founded on the conviction that exosomes/EVs will become a new class of medicines to treat a many medical conditions. [Read more…]
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 27
- Next Page »